About Palmitoyltransferase ZDHHC23
Palmitoyltransferase ZDHHC23 (ZDHHC23) is a protein
from Homo sapiens identified by UniProt accession
Q8IYP9, 409 residues long.
MolForge cross-references it against 0 known binders and
77 disease associations.
Target properties
| Protein name | Palmitoyltransferase ZDHHC23 |
| UniProt accession | Q8IYP9 |
| Gene | ZDHHC23 |
| Organism | Homo sapiens |
| Length | 409 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (77)
Diseases linked to this target (Open Targets).
- PHF-tau measurement · score 0.30
- blood protein measurement · score 0.10
- Fuchs endothelial corneal dystrophy · score 0.06
- X-linked endothelial corneal dystrophy · score 0.05
- Familial ocular anterior segment mesenchymal dysgenesis · score 0.05
- granular corneal dystrophy type I · score 0.05
- Cataract-microcornea syndrome · score 0.05
- glioblastoma multiforme · score 0.05
- attention deficit hyperactivity disorder · score 0.04
- macular corneal dystrophy · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IYP9-F1 | alphafold | PREDICTED | 78.54 | — |
Amino-acid sequence (409 residues)
MTQKGSMKPV KKKKTEEPEL EPLCCCEYID RNGEKNHVAT CLCDCQDLDE GCDRWITCKS LQPETCERIM DTISDRLRIP WLRGAKKVNI SIIPPLVLLP VFLHVASWHF LLGVVVLTSL PVLALWYYYL THRRKEQTLF FLSLGLFSLG YMYYVFLQEV VPKGRVGPVQ LAVLTCGLFL ILLALHRAKK NPGYLSNPAS GDRSLSSSQL ECLSRKGQEK TKGFPGADMS GSLNNRTTKD DPKGSSKMPA GSPTKAKEDW CAKCQLVRPA RAWHCRICGI CVRRMDHHCV WINSCVGESN HQAFILALLI FLLTSVYGIT LTLDTICRDR SVFTALFYCP GVYANYSSAL SFTCVWYSVI ITAGMAYIFL IQLINISYNV TEREVQQALR QKTGRRLLCG LIVDTGLLG
Explore Palmitoyltransferase ZDHHC23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets